drugset / Trial / NCT00106366

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

NCT00106366

Phase 3 Completed 389 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in combination with insulin aspart for the control of blood glucose in patients with Type 2 diabetes.

Timeline

Start
2005-03
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin detemir Protein / enzyme biologic
Subject insulin glargine Protein / enzyme biologic
Background insulin aspart Protein / enzyme biologic